THE DEAL, AT A GLANCE
From the announcementKailera Therapeutics
01Who is involvedBacked by Foresite Capital, General AtlanticFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02What happenedKailera Therapeutics raised $600M Series BFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersKailera Therapeutics is positioned around obesity therapeutics through KAI-9531, using Series B capital to advance clinical trials for obesity in a market described as…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Kailera Therapeutics · Financing Record
Explore source-linked visual explanations for Kailera Therapeutics. Unsupported claims are withheld while source review continues.
Record 137 · Recorded date: Needs review
What it does
Kailera Therapeutics is developing a broad and differentiated portfolio of clinical-stage injectable and oral GLP-1 therapies for clinical obesity, chronic weight management and related conditions.
Source: kailera.com ↗